H. Starr

发表

Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study

T. Spencer, L. Adler, J. Palumbo, 2009, Journal of clinical psychopharmacology.

Case study: audio feedforward treatment of selective mutism.

N. Blum, P. Dowrick, M. Osborne, 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections

S. Gopal, C. Benson, I. Turkoz, 2022, Neuropsychiatric Disease and Treatment.

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey

P. Lefebvre, D. Pilon, M. Zhdanava, 2022, Neuropsychiatric disease and treatment.

NDT_A_373725 1927..1937

S. Gopal, C. Benson, I. Turkoz, 2022 .

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

P. Lefebvre, D. Pilon, M. Zhdanava, 2022, Neuropsychiatric disease and treatment.

NDT_A_379985 2003..2019

P. Lefebvre, D. Pilon, M. Zhdanava, 2022 .

Methylphenidate in Children With ADHD With or Without Learning Disability

D. Murray, S. Ascher, H. Starr, 2014, Journal of attention disorders.

Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Titration, 1-Year Study

L. Adler, J. Palumbo, K. Cooper, 2011, Journal of clinical psychopharmacology.

Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study

L. Alphs, J. Bermak, L. Mao, 2017, Schizophrenia Research.

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

J. Lindenmayer, L. Alphs, C. Benson, 2015, The Journal of clinical psychiatry.

Effects of OROS Methylphenidate on Academic, Behavioral, and Cognitive Tasks in Children 9 to 12 Years of Age With Attention-Deficit/Hyperactivity Disorder

D. Murray, A. Childress, Robert B. Armstrong, 2011, Clinical pediatrics.

Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study

P. Ciccone, J. Kemner, Christa Hooper-Wood, 2005, Advances in therapy.

Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent‐onset versus more chronic schizophrenia and a history of criminal justice system involvement

L. Alphs, C. Bossie, L. Mao, 2015, Early intervention in psychiatry.

Telehealth-Based Psychoeducation for Caregivers: The Family Intervention in Recent-Onset Schizophrenia Treatment Study

K. Mueser, B. Mancevski, E. Achtyes, 2022, JMIR mental health.

Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis

F. Wiegand, L. Gibiansky, J. Massarella, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study

C. Demuro, E. Daly, J. Abell, 2020, Psychiatry Research.

Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD

S. Ascher, Robert B. Armstrong, L. Schwarzman, 2012, Journal of attention disorders.

Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

T. Wigal, S. Schuck, S. Wigal, 2011, Journal of child and adolescent psychopharmacology.

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.

J. Kemner, H. Starr, 2005, Journal of the National Medical Association.

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

L. Alphs, E. Muser, C. Kozma, 2015, Journal of medical economics.

A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia

L. Alphs, C. Benson, L. Mao, 2016, Schizophrenia Research.

Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.

J. Hulihan, L. Alphs, L. Mao, 2014, The Journal of clinical psychiatry.

Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.

Suneel K. Gupta, S. Wigal, H. Starr, 2011, Journal of child and adolescent psychopharmacology.

Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission.

A. Rostain, Yi-Wen Ma, D. Goodman, 2017, The Journal of clinical psychiatry.

OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder

H. Starr, K. McBurnett, Lynn Starr, 2011, Expert opinion on pharmacotherapy.

Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study

D. Fife, A. Sena, P. Hu, 2018, PLoS ONE.

Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis

F. Wiegand, L. Gibiansky, J. Massarella, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder

M. Trivedi, M. Thase, D. Ionescu, 2021, Depression and anxiety.

Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia

C. Correll, L. Alphs, Edward Kim, 2016, CNS Spectrums.